Pacific Biosciences of California Future Growth
Future criteria checks 1/6
Pacific Biosciences of California is forecast to grow earnings and revenue by 33.2% and 19.6% per annum respectively. EPS is expected to grow by 35.3% per annum. Return on equity is forecast to be -33.7% in 3 years.
Key information
33.2%
Earnings growth rate
35.3%
EPS growth rate
| Life Sciences earnings growth | 18.4% |
| Revenue growth rate | 19.6% |
| Future return on equity | -33.7% |
| Analyst coverage | Good |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 255 | -165 | -86 | -43 | 11 |
| 12/31/2025 | 192 | -198 | -122 | -108 | 13 |
| 12/31/2024 | 156 | -357 | -250 | -184 | 13 |
| 9/30/2024 | 173 | -394 | -240 | -233 | N/A |
| 6/30/2024 | 189 | -400 | -261 | -253 | N/A |
| 3/31/2024 | 200 | -297 | -249 | -240 | N/A |
| 12/31/2023 | 201 | -307 | -268 | -259 | N/A |
| 9/30/2023 | 170 | -309 | -274 | -262 | N/A |
| 6/30/2023 | 146 | -319 | -275 | -260 | N/A |
| 3/31/2023 | 134 | -321 | -296 | -279 | N/A |
| 12/31/2022 | 128 | -314 | -280 | -263 | N/A |
| 9/30/2022 | 137 | -299 | -249 | -234 | N/A |
| 6/30/2022 | 140 | -206 | -224 | -212 | N/A |
| 3/31/2022 | 135 | -175 | -176 | -167 | N/A |
| 12/31/2021 | 131 | -181 | -117 | -111 | N/A |
| 9/30/2021 | 122 | -37 | -97 | -94 | N/A |
| 6/30/2021 | 106 | -77 | -73 | -71 | N/A |
| 3/31/2021 | 92 | -59 | -80 | -79 | N/A |
| 12/31/2020 | 79 | 29 | 18 | 20 | N/A |
| 9/30/2020 | 80 | -46 | 14 | 16 | N/A |
| 6/30/2020 | 83 | -51 | 15 | 16 | N/A |
| 3/31/2020 | 90 | -53 | 21 | 22 | N/A |
| 12/31/2019 | 91 | -84 | -81 | -78 | N/A |
| 9/30/2019 | 82 | -115 | -82 | -79 | N/A |
| 6/30/2019 | 79 | -111 | -78 | -76 | N/A |
| 3/31/2019 | 76 | -109 | -76 | -73 | N/A |
| 12/31/2018 | 79 | -103 | -68 | -66 | N/A |
| 9/30/2018 | 84 | -93 | -71 | -68 | N/A |
| 6/30/2018 | 89 | -90 | N/A | -71 | N/A |
| 3/31/2018 | 88 | -93 | N/A | -70 | N/A |
| 12/31/2017 | 93 | -92 | N/A | -68 | N/A |
| 9/30/2017 | 94 | -90 | N/A | -60 | N/A |
| 6/30/2017 | 96 | -86 | N/A | -58 | N/A |
| 3/31/2017 | 97 | -79 | N/A | -64 | N/A |
| 12/31/2016 | 91 | -74 | N/A | -68 | N/A |
| 9/30/2016 | 101 | -57 | N/A | -56 | N/A |
| 6/30/2016 | 90 | -37 | N/A | -56 | N/A |
| 3/31/2016 | 94 | -31 | N/A | -44 | N/A |
| 12/31/2015 | 93 | -32 | N/A | -48 | N/A |
| 9/30/2015 | 73 | -49 | N/A | -63 | N/A |
| 6/30/2015 | 80 | -60 | N/A | -53 | N/A |
| 3/31/2015 | 67 | -67 | N/A | -59 | N/A |
| 12/31/2014 | 61 | -66 | N/A | -51 | N/A |
| 9/30/2014 | 53 | -64 | N/A | -51 | N/A |
| 6/30/2014 | 40 | -76 | N/A | -26 | N/A |
| 3/31/2014 | 34 | -77 | N/A | -29 | N/A |
| 12/31/2013 | 28 | -79 | N/A | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PACB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PACB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PACB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PACB's revenue (19.6% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: PACB's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PACB is forecast to be unprofitable in 3 years.